3898-66-6

Basic information

• Product Name: 4-NITROHOMOPHTHALIC ACID
• Synonyms: 4-NITROHOMOPHTHALIC ACID;2-(CARBOXYMETHYL)-5-NITROBENZOIC ACID
• CAS NO: 3898-66-6
• Molecular Formula: C₉H₇NO₆
• Molecular Weight: 225.15
• Mol File: 3898-66-6.mol
• Article Data: 12

Chemical Properties

• Melting Point: 210-215 °C (decomp)
• Boiling Point: 483.982°C at 760 mmHg
• Flash Point: 215.052°C
• Appearance: /
• Density: 1.594g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.639
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 2.73±0.22(Predicted)
• CAS DataBase Reference: 4-NITROHOMOPHTHALIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-NITROHOMOPHTHALIC ACID(3898-66-6)
• EPA Substance Registry System: 4-NITROHOMOPHTHALIC ACID(3898-66-6)

Safety Data

• Hazardous Substances Data: 3898-66-6(Hazardous Substances Data)

Usage

General Description

4-NITROHOMOPHTHALIC ACID is a chemical compound with the molecular formula C8H5NO6. It is a derivative of homophthalic acid, with a nitro group attached to the fourth carbon atom. 4-NITROHOMOPHTHALIC ACID is commonly used in the synthesis of various organic compounds, as a precursor for the preparation of dyes, pigments, and pharmaceuticals. It is a yellow crystalline solid that is sparingly soluble in water, and it has a melting point of around 240°C. 4-NITROHOMOPHTHALIC ACID is also used as a fluorescent probe in analytical chemistry and as an intermediate in the production of photoactive materials. Furthermore, it can be used in the preparation of metal-organic frameworks due to its ability to form coordination bonds with metal ions.

InChI:InChI=1/C9H7NO6/c11-8(12)3-5-1-2-6(10(15)16)4-7(5)9(13)14/h1-2,4H,3H2,(H,11,12)(H,13,14)

Upstream product

• 89-51-0 Homophthalic acid 
• 7697-37-2 nitric acid 
• 118-91-2 ortho-chlorobenzoic acid 
• 2516-96-3 2-chloro-5-nitrobenzoic acid 
• 95-13-6 1-indene 
• 645-45-4 hydrocinnamic acid chloride 
• 24623-37-8 6-nitro-indan-1,2-dione-2-oxime 
• 207554-21-0 6-nitro-1,2-indanedione 
• 24623-24-3 6-nitroindan-1-one 

Downstream Products

• 62252-24-8 2-methoxycarbonylmethyl-5-nitro-benzoic acid 
• 610-27-5 4-nitrophthalic acid 
• 52962-25-1 2-(carboxymethyl)-5-methoxybenzoic acid 
• 67755-25-3 2-carboxymethyl-5-hydroxybenzoic acid 
• 255376-41-1 5-methoxy-2-methoxycarbonylmethyl-benzoic acid methyl ester 
• 611187-01-0 7-nitro-l-oxo-3,4-dihydroisoquinolone 
• 62252-28-2 2-(2-ethoxy-2-oxoethyl)-5-nitrobenzoic acid 
• 1370022-12-0 C₁₆H₁₁NO₆ 
• 1370022-15-3 (3R,4R)-methyl 7-nitro-1-oxo-3-phenylisochroman-4-carboxylate 
• 1421604-87-6 2-(4-chloro-2-methoxycarbonyl-phenyl)-2-bromo-acetic acid methyl ester 
• 21640-24-4 methyl 5-hydroxy-2-(2-methoxy-2-oxoethyl)benzoate 
• 62351-60-4 Diaethyl-4-nitrohomophthalat 
• 444588-03-8 3,4-dihydro-7-nitro-1H-2-benzopyran 
• 149910-66-7 2-(2-(hydroxymethyl)-4-nitrophenyl)ethane-1-ol 

Relevant articles and documents

PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to a pyrazolopyrimidine derivative, a preparation method thereof and a pharmaceutical composition comprising the same as an active ingredient for the prevention or treatment of cancer, autoimmune disease and brain disease. The pyrazolopyrimidine derivative of the present invention exhibits excellent Bruton's tyrosine kinase inhibition activity, so that it can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease.

Design, synthesis and biological evaluation of 3-substituted indenoisoquinoline derivatives as topoisomerase I inhibitors

A new series of indenoisoquinoline derivatives was designed and synthesized. The in vitro anti-proliferative activity of these novel compounds was evaluated in HepG2, A549 and HCT-116 cell lines. Compounds 9a, 9b, 10a, 10c, 10e, 18a and 18b manifested potent inhibitory activity against the three tested cancer cell lines. Nineteen compounds were also tested for Top I inhibition at 50 μM. Almost all the tested compounds showed potent Top I inhibition activity at this concentration. The most potent compounds 9a and 10a demonstrated more cytotoxicity than HCPT and TPT and was comparable to CPT in inhibitory activities on Top I in our biological assay.

HCV PROTEASE INHIBITORS

The present invention discloses a compound of general formula (I); A is O, S, CH, NH or NR', when O links with Z3, Z1 is N or CRZ1, Z2 is CRZ2, when Z1 links with O, Z2 is CH, Z3 is C-Ar; Ra, Rb, Rc and Rd independently is H, OH, halogen or -Y1-Rm; A1 is NH or CH2; R1' is alkyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl; A2 is N, O or linking bond; R1 is hydrogen, or, R1 linking covalently with R3 forms C5-C9 saturated or unsaturated hydrocarbon chain substituted by O or N; R3 is alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted by cycloalky etc; R4 is alkoxy-CO, alkyl-NHCO, (alkyl)2NCO, or formyl substituted by aryl, cycloalkyl, heterocycloalkyl.